BioAtla
BCAB

$1.62

4.71%

Market Cap: 77.9M

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 65

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,056% more call options, than puts

Call options by funds: $505K | Put options by funds: $16K

29% more capital invested

Capital invested by funds: $66.6M [Q4 2023] → $85.5M (+$19M) [Q1 2024]

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

5% more funds holding

Funds holding: 79 [Q4 2023] → 83 (+4) [Q1 2024]

4.47% less ownership

Funds ownership: 56.49% [Q4 2023] → 52.02% (-4.47%) [Q1 2024]

21% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 29

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

209%

upside

Avg. target

$7.75

378%

upside

High target

$12

641%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Reni Benjamin	209%upside $5	Market Outperform Maintained	23 May 2024
HC Wainwright & Co. Arthur He	332%upside $7	Buy Reiterated	15 May 2024
JMP Securities Reni Benjamin	641%upside $12	Market Outperform Reiterated	28 Mar 2024
HC Wainwright & Co. Arthur He	332%upside $7	Buy Maintained	27 Mar 2024

See Analyst Rankings

Financial journalist opinion

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

24/7 Wall Street

3 Penny Stocks With 735% Average Upside, According to Wall Street

With the third quarter in full swing, the bulls have not lost their grip on equities.

3 Penny Stocks With 735% Average Upside, According to Wall Street

BioAtla to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.

BioAtla to Participate in the Jefferies Global Healthcare Conference

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, Chief Executive Officer and Co-Founder Eric Sievers – Chief Medical Officer Sheri Lydick – Chief Commercial Officer Richard Waldron – Chief Financial Officer Conference Call Participants Brian Cheng – JPMorgan Dev Prasad – Jefferies Kaveri Pohlman – BTIG Arthur He – H.C. Wainwright Tony Butler – EF Hutton Operator Greetings and welcome to the BioAtla First Quarter 2024 Earnings Call.

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and provided highlights on its clinical programs.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Citizens JMP Life Sciences Conference

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

BioAtla to Participate in the Citizens JMP Life Sciences Conference

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla is a biotech company focused on developing conditionally activated biologics for cancer therapy. Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules. BioAtla has promising pipeline candidates, including mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, with ongoing clinical studies.

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

See News Rankings